eASC

DRUG2 trials

Sponsors

Fundacion De Investigacion Biomedica De Salamanca, Tigenix S.A.U.

Conditions

Dry eye disease in patients with Graft versus Host disease patientsLocalized Adverse Reaction to Administration of Drug

Phase 1

Intralymphatic eASC Administration in Healthy Volunteers

CompletedNCT01743222

Tigenix S.A.U.Localized Adverse Reaction to Administration of Drug

Start: 2012-01-31End: 2012-06-30Updated: 2019-04-12

Phase 2

Phase IIB Clinical Trial to evaluate the efficacy and safety of Allogeneic Mesenchymal Stem Cell (MSC) eye injection treatment as therapy for Graft-versus-Host Disease (GvHD) refractory to conventional treatments

Not yet recruitingCTIS2024-519772-10-00

Fundacion De Investigacion Biomedica De SalamancaDry eye disease in patients with Graft versus Host disease patients

Target: 30Updated: 2025-11-20